Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PV Stock Forecast 2026-2027
$2.12
Current Price
$87.77M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PV Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PV Price Momentum
+33.3%
1 Week Change
+46.2%
1 Month Change
-2.8%
1 Year Change
+5.5%
Year-to-Date Change
-21.2%
From 52W High of $2.69
+105.8%
From 52W Low of $1.03
📊 TOP ANALYST CALLS
Did PV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Primavera Capital is one of their latest high-conviction picks.
Latest PV Stock Price Targets & Analyst Predictions
PV has shown a year-to-date change of 5.5% and a 1-year change of -2.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PV. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PV Analyst Ratings
0
Buy
0
Hold
0
Sell
PV Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.12
Latest PV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Primavera Capital Acquisition Corporation (PV) Competitors
The following stocks are similar to Primavera Capital based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PV
Primavera Capital
mkt cap
87.77M
Primavera Capital Acquisition Corporation (PV) Financial Data
Valuation Metrics
Market Cap
$87.77M
Enterprise Value
$0
P/E Ratio
30.0x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.2%
Current Ratio
0.5x
Debt/Equity
0.0x
ROE
+5.5%
ROA
+5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Primavera Capital Acquisition Corporation (PV) Business Model
About Primavera Capital Acquisition Corporation
What They Do
N/A
Business Model
N/A
Additional Information
N/A
Company Information
Primavera Capital Acquisition Corporation (PV) Latest News & Analysis
Latest News
Quick Summary
PharmaEssentia USA announced that the NCCN Guidelines now recommend ropeginterferon alfa-2b-njft (BESREMi®) for treatment, enhancing its position in hematology and oncology.
Why It Matters
The inclusion of BESREMi® in the NCCN Guidelines signals increased acceptance and potential market growth for PharmaEssentia's treatment, impacting stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia reported positive topline results from its SURPASS-ET trial for ropeginterferon alfa-2b-njft (P1101) in essential thrombocythemia, achieving its primary endpoint of durable responses.
Why It Matters
Positive trial results for PharmaEssentia's drug enhance its market potential, boosting investor confidence and likely influencing stock performance in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia Corporation has signed an exclusive licensing agreement with FORUS Therapeutics for the registration and distribution of BESREMi® in Canada, aimed at treating polycythemia vera.
Why It Matters
The licensing agreement expands PharmaEssentia's market reach for BESREMi®, potentially increasing revenue and market share in Canada, which is key for growth in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
A Frontier Economics study forecasts that Germany's grid-connected battery storage could rise to 60 GW by 2050, significantly increasing capacity and driving changes in energy supply dynamics.
Why It Matters
The projected growth of battery storage capacity in Germany to 60 GW by 2050 signals a transformative shift in energy supply, impacting energy companies, technology investments, and regulatory landscapes.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia USA announced results from a real-world data review published in the Journal of Clinical Oncology for the upcoming ASCO Annual Meeting. The company focuses on biologics in hematology and oncology.
Why It Matters
PharmaEssentia's real-world data review may impact investor confidence in its hematology and oncology products, influencing stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia USA Corporation announced the publication of an article in the British Journal of Clinical Pharmacology regarding the treatment of polycythemia with ropeginterferon alfa-2b.
Why It Matters
The publication highlights PharmaEssentia's advancements in hematology and oncology, potentially increasing investor confidence in its pipeline and driving stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PV Stock
What is Primavera Capital Acquisition Corporation's (PV) stock forecast for 2026?
Analyst forecasts for Primavera Capital Acquisition Corporation (PV) are not currently available. The stock is trading at $2.12.
Is PV stock a good investment in 2026?
Analyst ratings for PV are not currently available. The stock is currently trading at $2.12. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PV stock?
Price predictions from Wall Street analysts for PV are not currently available. The stock is trading at $2.12.
What is Primavera Capital Acquisition Corporation's business model?
N/A
What is the highest forecasted price for PV Primavera Capital Acquisition Corporation?
Price targets from Wall Street analysts for PV are not currently available. The stock is trading at $2.12.
What is the lowest forecasted price for PV Primavera Capital Acquisition Corporation?
Price targets from Wall Street analysts for PV are not currently available. The stock is trading at $2.12.
What is the overall PV consensus from analysts for Primavera Capital Acquisition Corporation?
Analyst ratings for PV are not currently available. The stock is trading at $2.12.
How accurate are PV stock price projections?
Stock price projections, including those for Primavera Capital Acquisition Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 7:28 AM UTC